The chemotherapy of tuberculosis: Past, present and future

International Journal of Tuberculosis and Lung Disease

Volumn 16, Issue 6, 2012, Pages 724-732

  Mitchison, Denis ^a   Davies, G ^b  

^a ST GEORGE'S UNIVERSITY OF LONDON   (United Kingdom)

^b UNIVERSITY OF LIVERPOOL   (United Kingdom)

Author keywords

Bacterial persistence; Drug resistance; New drugs; Treatment; Tuberculosis

Indexed keywords

6,7 DIHYDRO 2 NITRO 6 (4 TRIFLUOROMETHOXYBENZYLOXY) 5H IMIDAZO[2,1 B][1,3]OXAZINE; AMIKACIN; AMINOGLYCOSIDE ANTIBIOTIC AGENT; AMINOSALICYLIC ACID; BEDAQUILINE; CAPREOMYCIN; DELAMANID; ETHAMBUTOL; ETHIONAMIDE; ISONIAZID; LEVOFLOXACIN; MOXIFLOXACIN; PYRAZINAMIDE; QUINOLINE DERIVED ANTIINFECTIVE AGENT; RIFAMPICIN; RIFAPENTINE; STREPTOMYCIN; THIOACETAZONE;

ANTIBIOTIC SENSITIVITY; AREA UNDER THE CURVE; BACTERICIDAL ACTIVITY; CLINICAL TRIAL (TOPIC); COMBINATION CHEMOTHERAPY; CONVULSION; DISEASE MODEL; DRUG BINDING; DRUG EFFICACY; DRUG HALF LIFE; DRUG MECHANISM; DRUG MEGADOSE; DRUG POTENTIATION; DRUG RESISTANT TUBERCULOSIS; DRUG RESPONSE; DRUG TOLERANCE; EXTENSIVELY DRUG RESISTANT TUBERCULOSIS; HUMAN; LIVER TOXICITY; LOW DRUG DOSE; LUNG TUBERCULOSIS; MINIMUM INHIBITORY CONCENTRATION; MONOTHERAPY; MULTIDRUG RESISTANT TUBERCULOSIS; NONHUMAN; PERIPHERAL NEUROPATHY; PRIORITY JOURNAL; PROTEIN BINDING; REVIEW; SHORT COURSE THERAPY; SINGLE DRUG DOSE; TREATMENT DURATION; TUBERCULOSIS;

ANIMALS; ANTITUBERCULAR AGENTS; DRUG RESISTANCE, MULTIPLE, BACTERIAL; DRUG THERAPY; DRUGS, INVESTIGATIONAL; EXTENSIVELY DRUG-RESISTANT TUBERCULOSIS; FORECASTING; HISTORY, 20TH CENTURY; HISTORY, 21ST CENTURY; HUMANS; TREATMENT OUTCOME; TUBERCULOSIS; TUBERCULOSIS, MULTIDRUG-RESISTANT;

EID: 84861116576     PISSN: 10273719     EISSN: None     Source Type: Journal    
DOI: 10.5588/ijtld.12.0083     Document Type: Review

References (98)

1. Medical Research Council. Streptomycin treatment of pulmonary tuberculosis. BMJ 1948; 2: 769-782.
2. Fox W, Sutherland I, Daniels M. A five-year assessment of patients in a controlled trial of streptomycin in pulmonary tuberculosis. Q J Med 1954; 23: 347-366.
3. Medical Research Council. Treatment of pulmonary tuberculosis with streptomycin and para-amino-salicylic acid. BMJ 1950; 2: 1073-1085.
4. Fox W, Sutherland I. A five-year assessment of patients in a controlled trial of streptomycin, para-aminosalicylic acid and streptomycin plus para-aminosalicylic acid, in pulmonary tuberculosis. Q J Med 1956; 25: 221-243.
5. Donald P R, Sirgel F A, Botha F J, et al. The early bactericidal activity of isoniazid related to its dose size in pulmonary tuberculosis. Am J Respir Crit Care Med 1997; 156 (3 Pt 1): 895-900. (Pubitemid 27396432)
6. Medical Research Council. The treatment of pulmonary tuberculosis with isoniazid. BMJ 1952; 2: 735.
7. Medical Research Council. Isoniazid in the treatment of pulmonary tuberculosis. Second Report. BMJ 1953; 1: 521-536.
8. Fox W, Wiener A, Mitchison D A, Selkon J B, Sutherland I. The prevalence of drug-resistant tubercle bacilli in untreated patients with pulmonary tuberculosis: a national survey, 1955-56. Tubercle 1957; 38: 71-84.
9. Mitchison D A, Selkon J B. Bacteriological aspects of a survey of the incidence of drug-resistant tubercle bacilli among untreated patients. Tubercle 1957; 38: 85-98.
10. Crofton J. Chemotherapy of pulmonary tuberculosis. BMJ 1959; 1: 1610-1614.
11. Crofton J. Sputum conversion and the metabolism of isoniazid. Am Rev Tuberc 1958; 77: 869-871.
12. International Union Against Tuberculosis. An international investigation of the efficacy of chemotherapy in previously untreated patients with pulmonary tuberculosis. Bull Int Union Tuberc 1964: 34(2); 83-191.
13. East African/British Medical Research Council. Isoniazid with thiacetazone (thioacetazone) in the treatment of pulmonary tuberculosis in East Africa-fifth investigation. Tubercle 1970; 51: 123-151.
14. Tuberculosis Chemotherapy Centre, Madras. A concurrent comparison of home and sanatorium treatment of pulmonary tuberculosis in South India. Bull World Health Organ 1959; 21: 51-144.
15. Andrews R H, Devadatta S, Fox W, Radhakrishna S, Ramakrishnan C V, Velu S Prevalence of tuberculosis among close family contacts of tuberculous patients in South India, and influence of segregation of the patient on the early attack rate. Bull World Health Organ 1960; 23: 463-510.
16. Fox W. The problem of self-administration of drugs; with particular reference to pulmonary tuberculosis. Tubercle 1958; 39: 269-274.
17. McCune R M Jr, McDermott W, Tompsett R. The fate of Mycobacterium tuberculosis in mouse tissues as determined by the microbial enumeration technique. II. The conversion of tuberculous infection to the latent state by the administration of pyrazinamide and a companion drug. J Exp Med 1956; 104: 763-802.
18. Grumbach F. [Activity of rifampicin on experimental tuberculosis in mice. The development of resistance to rifampicin. Therapeutic effects of combinations of different drugs with rifampicin]. Antibiot Chemother 1970; 16: 392-405. [French]
19. East African/British Medical Research Council. Controlled clinical trial of short-course (6-month) regimens of chemotherapy for treatment of pulmonary tuberculosis. Lancet 1972; 299: 1079-1085.
20. Fox W, Ellard G A, Mitchison D A. Studies on the treatment of tuberculosis undertaken by the British Medical Research Council Tuberculosis Units, 1946-1986, with relevant subsequent publications. Int J Tuberc Lung Dis Int 1999; 3 (Suppl 2): S231-S279. (Pubitemid 29481843)
21. East African/British Medical Research Council. Controlled clinical trial of four short-course regimens of chemotherapy for two durations in the treatment of pulmonary tuberculosis. Third study. Second report. Tubercle 1980; 61: 59-69.
22. East African/British Medical Research Council. Controlled clinical trial of four 6-month regimens of chemotherapy for pulmonary tuberculosis. Second report. Am Rev Respir Dis 1976; 114: 471-475.
23. Santha T, Nazareth O, Krishnamurthy S, et al. Treatment of pulmonary tuberculosis with short course chemotherapy in South India-5-year follow-up. Tubercle 1989; 70: 229-234. (Pubitemid 20001742)
24. East African/British Medical Research Councils. Controlled clinical trial of five short-course (4-month) chemotherapy regimens in pulmonary tuberculosis: second report of the fourth study. Am Rev Respir Dis 1981; 123: 165-170.
25. East and Central African/British Medical Research Council (5th Collaborative Study). Controlled clinical trial of four short-course regimens of chemotherapy (three 6-month and one 8-month) for pulmonary tuberculosis: Final report. Tubercle 1986; 67: 5-15.
26. Hong Kong Chest Service/British Medical Research Council. Controlled trial of 2, 4 & 6 months of pyrazinamide in 6-month, 3× weekly regimens for smear-positive pulmonary tuberculosis, including an assessment of a combined preparation of isoniazid, rifampin and pyrazinamide. Am Rev Respir Dis 1991; 143: 700-706.
27. Mitchison D A. The action of anti-tuberculosis drugs in shortcourse chemotherapy. Tubercle 1985; 66: 218-225.
28. Jindani A, Nunn A J, Enarson D A. Two 8-month regimens of chemotherapy for treatment of newly diagnosed pulmonary tuberculosis: international multicentre randomised trial. Lancet 2004; 364: 1244-1251. (Pubitemid 39311345)
29. World Health Organization. Global tuberculosis control 2011. WHO/HTM/TB/2011.16. Geneva, Switzerland: WHO, 2011. http://www.who.int/tb/ publications/global-report/2011/gtbr11-full.pdf Accessed February 2012.
30. Orenstein E W, Basu S, Shah N S, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis 2009; 9: 53-61.
31. Johnston J C, Shahidi N C, Sadatsafavi M, Fitzgerald J M. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PLoS ONE 2009; 4: e6914.
32. David H L. Probability distribution of drug-resistant mutants in unselected populations of Mycobacterium tuberculosis. Appl Microbiol 1970; 20: 810-814.
33. Colijn C, Cohen T, Ganesh A, Murray M. Spontaneous emergence of multiple drug resistance in tuberculosis before and during therapy. PLoS ONE 2011; 8: e18327.
34. Shimao T. Drug resistance in tuberculosis control. Tubercle 1987; 68: 5-16.
35. Garton N J, Waddell S J, Sherratt A L, et al. Cytological and transcript analyses reveal fat and lazy persister-like bacilli in tuberculous sputum. PLoS Med 2008; 5: e75.
36. Allen B W, Mitchison D A. Counts of viable tubercle bacilli in sputum related to smear and culure grading. Med Lab Sci 1992; 49: 94-98.
37. Matthews J H. IX. Pyrazinamide and isoniazid used in the treatment of pulmonary tuberculosis. Am Rev Respir Dis 1960; 81: 348-351.
38. Mitchison D A. How drug resistance emerges as a result of poor compliance during short course chemotherapy for tuberculosis. Int J Tuberc Lung Dis 1998; 2: 10-15. (Pubitemid 28108937)
39. Srivastava S, Pasipanodya J G, Meek C, Left R, Gumbo T. Multidrug-resistant tuberculosis not due to non-compliance but to between-patient pharmacokinetic variability. J Infect Dis 2011; 204: 1951-1958.
40. East and Central African/British Medical Research Council. Controlled clinical trial of 4 short-course regimens of chemotherapy (three 6-month and one 8 month) for pulmonary tuberculosis. Tubercle 1983; 64: 163-168.
41. Hong Kong Tuberculosis Treatment Services and East African and British Medical Research Councils. First-line chemotherapy in the retreatment of bacteriological relapses of pulmonary tuberculosis following a short-course regimen. Lancet 1976; 1: 162-168.
42. Peloquin C. What is the 'right' dose of rifampin? Int J Tuberc Lung Dis 2003; 7: 3-5. (Pubitemid 36427025)
43. Rustomjee R, Lienhardt C, Kanyok T, et al. A Phase II study of the sterilizing activities of ofloxacin, gatifloxacin and moxifloxacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2008; 12: 128-138. (Pubitemid 351212403)
44. Mitchison D A, Selkon J B. The bactericidal activities of antituberculous drugs. Am Rev Tuberc 1956; 74 (2 Part 2): 109-116.
45. Shleeva M O, Bagramyan K, Telkov M V, Mukamolova G V, et al. Formation and resuscitation of 'non-culturable' cells of Rhodococcus rhodochrous and Mycobacterium tuberculosis in prolonged stationary phase. Microbiology 2002; 148: 1581-1591. (Pubitemid 34567236)
46. Wayne L G, Hayes L G. An in vitro model for sequential study of shiftdown of Mycobacterium tuberculosis through two stages of non-replicating persistence. Infect Immun 1996; 64: 2062-2069. (Pubitemid 26165667)
47. Hu Y, Mangan J A, Dhillon J, et al. Detection of mRNA transcripts and active transcription in persistent Mycobacterium tuberculosis induced by exposure to rifampin or pyrazinamide. J Bacteriol 2000; 182: 6358-6365.
48. Hu Y, Coates A R, Mitchison D A. Sterilising action of pyrazinamide in models of dormant and rifampicin-tolerant Mycobacterium tuberculosis. Int J Tuberc Lung Dis 2006; 10: 317-322.
49. Mukamolova G V, Turapov O, Malkin J, Woltmann G, Barer M R. Resuscitation-promoting factors reveal an occult population of tubercle bacilli in sputum. Am J Respir Crit Care Med 2010; 181: 174-180.
50. Shleeva M O, Kudykina Y K, Vostroknutova G N, Suzina N E, Mulyukin A L, Kaprelyants A S. Dormant ovoid cells of Mycobacterium tuberculosis are formed in response to gradual external acidification. Tuberculosis (Edinb) 2011; 91: 146-154.
51. Jindani A, Aber V R, Edwards E A, Mitchison D A. The early bactericidal activity of drugs in patients with pulmonary tuberculosis. Am Rev Respir Dis 1980; 121: 939-949. (Pubitemid 10118376)
52. Jindani A, Doré C J, Mitchison D A. The bactericidal and sterilising activities of antituberculosis drugs during the first 14 days. Am J Respir Crit Care Med 2003; 167: 1348-1354. (Pubitemid 36609718)
53. Sirgel F A, Fourie P B, Donald P R, et al The early bactericidal activities of rifampicin and rifapentine in pulmonary tuberculosis. Am J Respir Crit Care Med 2005; 172: 128-135. (Pubitemid 40923325)
54. Donald P R, Sirgel F A, Venter A, et al. The early bactericidal activity of streptomycin. Int J Tuberc Lung Dis 2002; 6: 693-698. (Pubitemid 34832149)
55. Elliott A M, Berning S E, Iseman M D, Peloquin C A. Failure of drug penetration and acquisition of drug resistance in chronic tuberculous empyema. Tubercle Lung Dis 1995; 76: 463-467.
56. Rustomjee R, Diacon A H, Allen J, et al. Early bactericidal activity and pharmacokinetics of the diarylquinoline TMC207 in treatment of pulmonary tuberculosis. Antimicrob Agents Chemother 2008; 52: 2831-2835.
57. Diacon A H, Dawson R, Hanekom M. Early bactericidal activity and pharmacokinetics of PA-824 in smear-positive tuberculosis patients. Antimicrob Agents Chemother 2010; 54: 3402-3407.
58. Jayaram R, Gaonkar S, Kaur P, et al. Pharmacokineticsp harmacodynamics of rifampin in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2003; 47: 2118-2124. (Pubitemid 36753560)
59. Jayaram R, Shandil R K, Gaonkar S, et al. Isoniazid pharmacokinetics- pharmacodynamics in an aerosol infection model of tuberculosis. Antimicrob Agents Chemother 2004; 48: 2951-2957. (Pubitemid 38989160)
60. Shandil R K, Jayaram R, Kaur P, et al. Moxifloxacin, ofloxacin, sparfloxacin, and ciprofloxacin against Mycobacterium tuberculosis: evaluation of in vitro and pharmacodynamic indices that best predict in vivo efficacy. Antimicrob Agents Chemother 2007; 51: 576-582. (Pubitemid 46185275)
61. Mitchison D A. Plasma concentrations of isoniazid in the treatment of tuberculosis. In: Davies D S, Pritchard B N C, eds. Biological effects of drugs in relation to their plasma concentrations. New York, NY, USA: Macmillan, 1973: pp 169-182.
62. Mitchison D A. Antimicrobial therapy of tuberculosis: justification for currently recommended treatment regimens. Seminars Respir Crit Care Med 2004; 25: 307-315. (Pubitemid 38857283)
63. Mitchison D A. PK/PD and the choice of high dosage rifamycins. Int J Tuberc Lung Dis 2012; 16 (in press).
64. Da Silva P E A, Palomino J C. Molecular basis and mechanisms of drug resistance in Mycobacterium tuberculosis classical and new drugs. J Antimicrob Chemother 2011; 66: 1417-1430.
65. Biehl J P, Vilter R W. Effects of isoniazid on pyridoxine metabolism. J Am Med Assoc 1954; 156: 1549-1552.
66. van der Watt J J, Harrison T B, Benatar M, Heckmann J M. Polyneuropathy, anti-tuberculosis treatment and the role of pyridoxine in the HIV/AIDS era: a systematic review. Int J Tuberc Lung Dis 2011; 15: 722-728.
67. Brindle R, Odhiambo J, Mitchison D. Serial counts of Mycobacterium tuberculosis in sputum as surrogate markers of the sterilising activity of rifampicin and pyrazinamide in treating pulmonary tuberculosis. BMC Pulm Med 2001; 1: 2.
68. Mitchison D A. Role of individual drugs in the chemotherapy of tuberculosis. Int J Tuberc Lung Dis 2000; 4: 796-806.
69. Awaness A M, Mitchison D A. Cumulative effects of pulsed exposures of Mycobacterium tuberculosis to isoniazid. Tubercle 1973; 54: 153-158.
70. Mitchison D A. Rifapentine: the way forward. Int J Tuberc Lung Dis 1998; 2: 612-615.
71. Zhang Y, Mitchison D. The curious characteristics of pyrazinamide: a review. Int J Tuberc Lung Dis 2003; 7: 6-21. (Pubitemid 36427026)
72. Mitchison D A, Zhang Y. Recent developments in the study of pyrazinamide: an update. In: Donald P, van Helden P D. Antituberculosis chemotherapy. Progress in respiratory research, Vol 40. Cape Town, South Africa: Karger, 2011: pp 32-43.
73. Shi W, Zhang X, Jiang X, et al. Pyrazinamide inhibits transtranslation in Mycobacterium tuberculosis. Science 2011; 333: 1630-1632.
74. Mitchison D A. The segregation of streptomycin-resistant variants of Mycobacterium tuberculosis into groups with characteristic levels of resistance. J Gen Microbiol 1953; 5: 596-604.
75. Donald P R, Sirgel F A, Venter A, et al. The early bactericidal activity of amikacin in pulmonary tuberculosis. Int J Tuberc Lung Dis 2001; 5: 533-538. (Pubitemid 32587283)
76. Crowle A J, Sbarbaro J A, Judson F N, Douvas G S, May M H. Inhibition by streptomycin of tubercle bacilli within cultured human macrophages. Am Rev Respir Dis 1984; 130: 839-844. (Pubitemid 15209571)
77. Wallace J G. The heat resistance of tubercle bacilli in the lungs of infected mice. Am Res Respir Dis 1961; 83: 866-871.
78. Rees R J W, Hart P D. Analysis of the host-parasite equilibrium in chronic murine tuberculosis by total and viable bacillary counts. Br J Exp Pathol 1961; 41: 83-88.
79. Mitchison D A, Chang K C. Experimental models of tuberculosis: can we trust the mouse? Am J Respir Crit Care Med 2009; 180: 201-202.
80. Almeida D, Nuermberger E, Tasneen R, et al. Paradoxical effect of isoniazid on the activity of rifampin-pyrazinamide combination in a mouse model of tuberculosis. Antimicrob Agents Chemother 2009; 53: 4178-4184.
81. Nuermberger E L, Yoshimatsu T, Tyagi S, et al. Moxifloxacincontaining regimen greatly reduces time to culture conversion in murine tuberculosis. Am J Respir Crit Care Med 2004; 169: 421-426. (Pubitemid 38134824)
82. Nuermberger E L, Yoshimatsu T, Tyagi S, et al. Moxifloxacincontaining regimens of reduced duration produce a stable cure in murine tuberculosis. Am J Respir Crit Care Med 2004; 170: 1131-1134. (Pubitemid 39488628)
83. Dorman S E, Johnson J L, Goldberg S, et al. Substitution of moxifloxacin for isoniazid during intensive phase treatment of pulmonary tuberculosis. Am J Respir Crit Care Med 2009; 180: 273-228.
84. Rosenthal I M, Zhang M, Williams K N, et al. Daily dosing of rifapentine cures tuberculosis in three months or less in the murine model. PLoS Med 2007; 4: e344.
85. Dorman S E, Goldberg S, Feng P, et al. A Phase II study of a rifapentine-containing regimen for intensive phase treatment of pulmonary tuberculosis: preliminary results for Tuberculosis Trials Consortium Study 29. Am J Respir Crit Care Med 2011; 183: A6413.
86. Chigutsa E, Visser M E, Swart E C, et al. The SLCO1B1 rs4149032 polymorphism is highly prevalent in South Africans and is associated with reduced rifampin concentrations: dosing implications. Antimicrob Agents Chemother 2011; 55: 4122-4127.
87. Wilkins J J, Savic R M, Karlsson M O, et al. Population pharmacokinetics of rifampin in pulmonary tuberculosis patients, including a semi-mechanistic model to describe variable absorption. Antimicrob Agents Chemother 2008; 52: 2138-2148. (Pubitemid 351758551)
88. Verbist L. Pharmacological study of rifampicin after repeated high dosage during intermittent combined therapy. I. Variation of rifampicin serum levels (947 determinations). Respiration 1971; 28 (Suppl): S7-S16.
89. Dooley K E, Bliven-Sizemore E, Weiner M, et al. A Phase I dose escalation trial of the pharmacokinetics, safety, and tolerability of rifapentine dosed daily in healthy volunteers: preliminary results from Tuberculosis Trials Consortium Study 29. Am J Respir Crit Care Med 2011; 183: A6341.
90. Mitchison D A, Fourie P B. The near future: improving the activity of rifamycins and pyrazinamide. Tuberculosis (Edin) 2010; 90: 177-181.
91. Andries K, Verhasselt P, Guillemont J, et al. A diarylquinoline drug active on the ATP synthase of Mycobacterium tuberculosis. Science 2005; 307: 223.
92. Dhillon J, Andries K, Phillips P P, Mitchison D A. Bactericidal activity of the diarylquinoline TMC207 against Mycobacterium tuberculosis outside and within cells. Tuberculosis (Edinb) 2010; 90: 301-305.
93. Koul A, Vranckx L, Dendouga N, et al. Diarylquinolines are bactericidal for dormant mycobacteria as a result of disturbed ATP homeostasis. J Biol Chem 2008; 283: 25273-25280.
94. Ibrahim M, Andries K, Lounis N, et al. Synergistic activity of R207910 combined with pyrazinamide against murine tuberculosis. Antimicrob Agents Chemother 2007; 51: 1011-1015. (Pubitemid 46355288)
95. Diacon A H, Pym A, Grobusch M, et al. The diarylquinoline TMC207 for multidrug-resistant tuberculosis. N Engl J Med 2009; 360: 2397-2405.
96. Manjunatha U, Boshoff H I, Barry C E. The mechanism of action of PA-824: novel insights from transcriptional profiling. Commun Integr Biol 2009; 2: 215-218.
97. Hurdle J G, O'Neill A J, Chopra I, Lee R E. Targeting bacterial membrane function: an underexploited mechanism for treating persistent infections. Nat Rev Microbiol 2011; 9: 62-75.
98. Diacon A H, Dawson R, Hanekom M, et al. Early bactericidal activity of delamanid (OPC-67683) in smear-positive pulmonary tuberculosis patients. Int J Tuberc Lung Dis 2011; 15: 949-954.